This article is more than 5 years old. Information may no longer be current.
VEGF-inhibitor axitinib valid second-line treatment for RCC
Click Here to Manage Email Alerts
Patients with renal cell carcinoma who have progressed despite prior treatment had longer PFS when assigned to axitinib compared with patients to assigned to sorafenib.
In addition, the results of a phase 3, randomized, multicenter study indicated that axitinib also conferred a significantly longer objective response rate, suggesting that axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma (RCC), according to the researchers.
In the study, 723 patients from 175 sites in 22 countries were randomly assigned to treatment with 5 mg daily axitinib (n=361) or 400 mg twice daily sorafenib (n=362). All patients had confirmed renal cell carcinoma but had progressed despite prior treatment with sunitinib (54%), cytokines (35%), bevacizumab (8%) or temsirolimus (3%).
Patients assigned to axitinib had significantly longer PFS vs. sorafenib (6.7 months vs. 4.7 months; P<.0001).
Objective response rate was assessed by a masked independent radiology review committee. Patients assigned to axitinib had an objective response of 19%, compared with 9% for patients assigned to sorafenib (P=.0001).
Four percent of patients in the axitinib group had to discontinue treatment due to adverse events, compared with 8% of patients in the sorafenib group.
For more information:
- Rini BI. Lancet. 2011;doi:10.1016/S0140-6736(11)61613-9.